医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

2014年11月13日 AM10:57
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ:4573):

Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited (“Takeda”) and certain affiliates of Takeda, have filed a patent infringement lawsuit against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s), which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of the 8 mcg and 24 mcg AMITIZA® (lubiprostone) oral capsules. (For more details, please refer to Sucampo’s release dated November 12, 2014)

As a result of Sucampo’s filing of the said lawsuit, final FDA approval of Dr. Reddy’s’s ANDA will be stayed up to 30 months from October 3, 2014.

The said filing will have no impact on the forecast of business results for the fiscal year ending March 2015.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/141113_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists